PROK
ProKidney Corp.
Biotechnology
Market Cap$296M
5Y Perf.-81.6%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
PROK vs RGEN vs BEAM vs ACAD
Revenue, margins, valuation, and 5-year total return — side by side.
RGEN
Repligen Corporation
Medical - Instruments & Supplies
Market Cap$6.96B
5Y Perf.-38.1%
BEAM
Beam Therapeutics Inc.
Biotechnology
Market Cap$3.32B
5Y Perf.-74.9%
ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology
Market Cap$3.84B
5Y Perf.-8.2%
PROK vs RGEN vs BEAM vs ACAD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PROK | RGEN | BEAM | ACAD |
|---|---|---|---|---|
| Industry | Biotechnology | Medical - Instruments & Supplies | Biotechnology | Biotechnology |
| Market Cap | $296M | $6.96B | $3.32B | $3.84B |
| Revenue (TTM) | $893K | $763M | $132M | $1.10B |
| Net Income (TTM) | $-69M | $51M | $-65M | $376M |
| Gross Margin | -218.8% | 51.5% | -64.2% | 91.5% |
| Operating Margin | -184.8% | 8.7% | -281.0% | 7.4% |
| Forward P/E | — | 61.7x | — | 55.6x |
| Total Debt | $3M | $690M | $294M | $52M |
| Cash & Equiv. | $109M | $566M | $295M | $178M |
PROK vs RGEN vs BEAM vs ACAD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PROK
RGEN
BEAM
ACAD
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| ProKidney Corp. (PROK) | 100 | 18.4 | -81.6% |
| Repligen Corporation (RGEN) | 100 | 61.9 | -38.1% |
| Beam Therapeutics I… (BEAM) | 100 | 25.1 | -74.9% |
| ACADIA Pharmaceutic… (ACAD) | 100 | 91.8 | -8.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PROK vs RGEN vs BEAM vs ACAD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ACAD leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. ProKidney Corp. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
PROK
ProKidney Corp.
The Growth Leader
PROK is the #2 pick in this set and the best alternative if growth and momentum is your priority.
- 10.8% revenue growth vs ACAD's 11.9%
- +165.7% vs RGEN's -3.4%
Best for: growth and momentum
RGEN
Repligen Corporation
The Long-Run Compounder
RGEN is the clearest fit if your priority is long-term compounding.
- 358.2% 10Y total return vs ACAD's -23.4%
Best for: long-term compounding
BEAM
Beam Therapeutics Inc.
The Growth Play
BEAM is the clearest fit if your priority is growth exposure and defensive.
- Rev growth 120.0%, EPS growth 82.3%, 3Y rev CAGR 31.9%
- Beta 2.08, current ratio 13.09x
Best for: growth exposure and defensive
ACAD
ACADIA Pharmaceuticals Inc.
The Income Pick
ACAD carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.11
- Lower volatility, beta 1.11, Low D/E 4.3%, current ratio 3.83x
- Better valuation composite
- 34.3% margin vs PROK's -77.3%
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PROK | 10.8% revenue growth vs ACAD's 11.9% |
| Value | ACAD | Better valuation composite |
| Quality / Margins | ACAD | 34.3% margin vs PROK's -77.3% |
| Stability / Safety | ACAD | Beta 1.11 vs PROK's 2.94 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | PROK | +165.7% vs RGEN's -3.4% |
| Efficiency (ROA) | ACAD | 26.2% ROA vs PROK's -18.8%, ROIC 10.0% vs -49.4% |
PROK vs RGEN vs BEAM vs ACAD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
Segment breakdown not available.
FY 2018
PROK vs RGEN vs BEAM vs ACAD — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACADLAGGINGBEAM
Who Leads Where
ACAD leads in 4 of 6 categories
PROK leads 0 • RGEN leads 0 • BEAM leads 0 • 1 tied
Explore the data ↓BEAMBeam Therapeutics Inc.
0leads
RGENRepligen Corporation
0leads
PROKProKidney Corp.
0leads
ACADACADIA Pharmaceutical…
4leads
6 Total Categories
CATEGORYLEADERvs PROKvs RGENMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ACAD3/6
Valuation MetricsMultiples, price ratios, and targets
ACAD4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACAD5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
ACAD3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ACAD leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACAD is the larger business by revenue, generating $1.1B annually — 1226.5x PROK's $893,000. ACAD is the more profitable business, keeping 34.3% of every revenue dollar as net income compared to PROK's -77.3%. On growth, PROK holds the edge at +196.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | PROKProKidney Corp. | RGENRepligen Corporat… | BEAMBeam Therapeutics… | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $893,000 | $763M | $132M | $1.1B |
| EBITDAEarnings before interest/tax | -$159M | $155M | -$355M | $96M |
| Net IncomeAfter-tax profit | -$69M | $51M | -$65M | $376M |
| Free Cash FlowCash after capex | -$130M | $104M | -$384M | $212M |
| Gross MarginGross profit ÷ Revenue | -2.2% | +51.5% | -64.2% | +91.5% |
| Operating MarginEBIT ÷ Revenue | -184.8% | +8.7% | -2.8% | +7.4% |
| Net MarginNet income ÷ Revenue | -77.3% | +6.7% | -49.2% | +34.3% |
| FCF MarginFCF ÷ Revenue | -145.1% | +13.7% | -2.9% | +19.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +196.1% | +14.8% | -100.0% | +9.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +17.6% | +50.0% | +26.6% | -81.8% |
ACAD leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
ACAD leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 9.8x trailing earnings, ACAD trades at a 93% valuation discount to RGEN's 143.6x P/E. On an enterprise value basis, ACAD's 26.7x EV/EBITDA is more attractive than RGEN's 51.2x.
| Metric | PROKProKidney Corp. | RGENRepligen Corporat… | BEAMBeam Therapeutics… | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| Market CapShares × price | $296M | $7.0B | $3.3B | $3.8B |
| Enterprise ValueMkt cap + debt − cash | $191M | $7.1B | $3.3B | $3.7B |
| Trailing P/EPrice ÷ TTM EPS | -3.65x | 143.59x | -39.90x | 9.78x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 61.74x | — | 55.62x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 51.25x | — | 26.71x |
| Price / SalesMarket cap ÷ Revenue | 331.72x | 9.43x | 23.76x | 3.58x |
| Price / BookPrice ÷ Book value/share | 0.83x | 3.32x | 2.58x | 3.13x |
| Price / FCFMarket cap ÷ FCF | — | 74.17x | — | 36.48x |
ACAD leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
ACAD leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ACAD delivers a 35.6% return on equity — every $100 of shareholder capital generates $36 in annual profit, vs $-21 for PROK. PROK carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to RGEN's 0.33x. On the Piotroski fundamental quality scale (0–9), RGEN scores 7/9 vs PROK's 2/9, reflecting strong financial health.
| Metric | PROKProKidney Corp. | RGENRepligen Corporat… | BEAMBeam Therapeutics… | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -20.8% | +2.5% | -5.9% | +35.6% |
| ROA (TTM)Return on assets | -18.8% | +1.8% | -4.6% | +26.2% |
| ROICReturn on invested capital | -49.4% | +2.2% | -31.1% | +10.0% |
| ROCEReturn on capital employed | -46.5% | +2.2% | -33.3% | +10.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 7 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.01x | 0.33x | 0.24x | 0.04x |
| Net DebtTotal debt minus cash | -$106M | $124M | -$1M | -$126M |
| Cash & Equiv.Liquid assets | $109M | $566M | $295M | $178M |
| Total DebtShort + long-term debt | $3M | $690M | $294M | $52M |
| Interest CoverageEBIT ÷ Interest expense | -38532.25x | 2.64x | 1.08x | — |
ACAD leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
ACAD leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACAD five years ago would be worth $10,657 today (with dividends reinvested), compared to $1,840 for PROK. Over the past 12 months, PROK leads with a +165.7% total return vs RGEN's -3.4%. The 3-year compound annual growth rate (CAGR) favors ACAD at 1.3% vs PROK's -41.7% — a key indicator of consistent wealth creation.
| Metric | PROKProKidney Corp. | RGENRepligen Corporat… | BEAMBeam Therapeutics… | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -16.6% | -24.9% | +19.1% | -14.3% |
| 1-Year ReturnPast 12 months | +165.7% | -3.4% | +87.4% | +32.3% |
| 3-Year ReturnCumulative with dividends | -80.2% | -21.1% | -3.1% | +3.9% |
| 5-Year ReturnCumulative with dividends | -81.6% | -29.5% | -49.6% | +6.6% |
| 10-Year ReturnCumulative with dividends | -81.6% | +358.2% | +72.4% | -23.4% |
| CAGR (3Y)Annualised 3-year return | -41.7% | -7.6% | -1.0% | +1.3% |
ACAD leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — BEAM and ACAD each lead in 1 of 2 comparable metrics.
Risk & Volatility
ACAD is the less volatile stock with a 1.11 beta — it tends to amplify market swings less than PROK's 2.94 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BEAM currently trades 88.7% from its 52-week high vs PROK's 26.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PROKProKidney Corp. | RGENRepligen Corporat… | BEAMBeam Therapeutics… | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.94x | 1.71x | 2.08x | 1.11x |
| 52-Week HighHighest price in past year | $7.13 | $175.77 | $36.44 | $27.81 |
| 52-Week LowLowest price in past year | $0.54 | $109.52 | $15.35 | $14.68 |
| % of 52W HighCurrent price vs 52-week peak | +26.1% | +70.3% | +88.7% | +80.5% |
| RSI (14)Momentum oscillator 0–100 | 46.0 | 55.9 | 57.7 | 53.8 |
| Avg Volume (50D)Average daily shares traded | 817K | 911K | 2.0M | 1.7M |
Evenly matched — BEAM and ACAD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: PROK as "Buy", RGEN as "Buy", BEAM as "Buy", ACAD as "Buy". Consensus price targets imply 151.1% upside for PROK (target: $5) vs 26.3% for BEAM (target: $41).
| Metric | PROKProKidney Corp. | RGENRepligen Corporat… | BEAMBeam Therapeutics… | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $4.67 | $163.67 | $40.83 | $34.78 |
| # AnalystsCovering analysts | 7 | 23 | 27 | 37 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACAD leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallACADIA Pharmaceuticals Inc. (ACAD)Leads 4 of 6 categories
Loading custom metrics...
PROK vs RGEN vs BEAM vs ACAD: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is PROK or RGEN or BEAM or ACAD a better buy right now?
For growth investors, ProKidney Corp.
(PROK) is the stronger pick with 1075% revenue growth year-over-year, versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 8x trailing P/E (55. 6x forward), making it the more compelling value choice. Analysts rate ProKidney Corp. (PROK) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PROK or RGEN or BEAM or ACAD?
On trailing P/E, ACADIA Pharmaceuticals Inc.
(ACAD) is the cheapest at 9. 8x versus Repligen Corporation at 143. 6x. On forward P/E, ACADIA Pharmaceuticals Inc. is actually cheaper at 55. 6x.
03Which is the better long-term investment — PROK or RGEN or BEAM or ACAD?
Over the past 5 years, ACADIA Pharmaceuticals Inc.
(ACAD) delivered a total return of +6. 6%, compared to -81. 6% for ProKidney Corp. (PROK). Over 10 years, the gap is even starker: RGEN returned +358. 2% versus PROK's -81. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PROK or RGEN or BEAM or ACAD?
By beta (market sensitivity over 5 years), ACADIA Pharmaceuticals Inc.
(ACAD) is the lower-risk stock at 1. 11β versus ProKidney Corp. 's 2. 94β — meaning PROK is approximately 164% more volatile than ACAD relative to the S&P 500. On balance sheet safety, ProKidney Corp. (PROK) carries a lower debt/equity ratio of 1% versus 33% for Repligen Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — PROK or RGEN or BEAM or ACAD?
By revenue growth (latest reported year), ProKidney Corp.
(PROK) is pulling ahead at 1075% versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). On earnings-per-share growth, the picture is similar: Repligen Corporation grew EPS 287. 0% year-over-year, compared to 17. 7% for ProKidney Corp.. Over a 3-year CAGR, BEAM leads at 31. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PROK or RGEN or BEAM or ACAD?
ACADIA Pharmaceuticals Inc.
(ACAD) is the more profitable company, earning 36. 5% net margin versus -169. 8% for ProKidney Corp. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -184. 8% for PROK. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PROK or RGEN or BEAM or ACAD more undervalued right now?
On forward earnings alone, ACADIA Pharmaceuticals Inc.
(ACAD) trades at 55. 6x forward P/E versus 61. 7x for Repligen Corporation — 6. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PROK: 151. 1% to $4. 67.
08Which pays a better dividend — PROK or RGEN or BEAM or ACAD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is PROK or RGEN or BEAM or ACAD better for a retirement portfolio?
For long-horizon retirement investors, ACADIA Pharmaceuticals Inc.
(ACAD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 11)). ProKidney Corp. (PROK) carries a higher beta of 2. 94 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACAD: -23. 4%, PROK: -81. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PROK and RGEN and BEAM and ACAD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PROK is a small-cap high-growth stock; RGEN is a small-cap high-growth stock; BEAM is a small-cap high-growth stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(PROK: 196.1% · RGEN: 14.8%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.